

Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: an international multicentre clinical trial

Filippo Murina^{a#}, Ciprian Crişan^b, Marius Biriş^c, Daniela Sîrbu^d, Dionisio Franco Barattini^e, Luca Ivan Ardolino^f, Elena Casolati^g

^a: Lower Genital Tract Disease Unit, V. Buzzi Hospital-University of Milan, Italy

^b: Clinica Medicală Dr. Crişan Ciprian, Timișoara, România

^c: Clinica Medicală Biriş Marius, Timișoara, România

^d: Clinica Medicală Dr. Sîrbu Daniela, Timișoara, România

^e: Opera CRO, a TIGERMED Group company, Timișoara, România

^f: Effik Italia, Milan, Italy

^g: Private Practice of Obstetrics and Gynecology, Milan, Italy

Running title: POLARIS: Polybactum[®] to assess Recurrent Bacterial Vaginosis

#Address correspondence to Filippo Murina, filippo.murina@asst-fbf-sacco.it

Filippo Murina	filippo.murina@asst-fbf-sacco.it	Lower Genital Tract Disease Unit, Vittore Buzzi Hospital-University of Milan, Via Lodovico Castelvetro, 32 - 20154 Milano Italy
Ciprian Crişan	drcipriancrisan@gmail.com	Clinica Medicală Dr. Crişan Ciprian, Strada Salcânilor 22, Timișoara 300425, România
Marius Biriş	marius308@yahoo.com	Clinica Medicală Biriş Marius, Bd 16 Decembrie 1989 22-24, Timișoara, România
Daniela Sîrbu	sirbudaniela47@yahoo.com	Clinica Medicală Dr. Sîrbu Daniela, Str. Sfinții Apostoli Petru și Pavel 15, Timișoara, 300269 România
Dionisio Franco Barattini	barattini@operacro.com	Opera CRO, a TIGERMED Group company, Strada Cozia 10, Timișoara 300209 România
Luca Ivan Ardolino	Luca.Ardolino@effikitalia.it	Effik Italia, Via dei Lavoratori, 54 - 20092 Cinisello Balsamo Milano, Italy
Elena Casolati	ecasolati@tin.it	Private Practice of Obstetrics and Gynecology, Altamedica Milano, L. Ildefonso Schuster, 1 - 20122 Milano, Italy

ABSTRACT

Several risk factors have been identified but the etiology and pathogenesis of Bacterial vaginosis (BV) are still not completely understood, and the recurrence rate of BV remains high despite adequate chemotherapy treatment.

The primary objective of the study was to assess the effectiveness of a new vaginal medical device, which contains polycarbophil, 0.04 % lauryl glucoside, and glycerides (Polybactum® - Effik Italia), in reducing BV recurrence rate.

This was a multicenter, open label, not comparative study performed in Italy and Romania. Female subjects over 18-years-old affected by recurrent BV were included. The latest episode was diagnosed by Amsel criteria 6-9 days before the start of the study and treated with vaginal metronidazole (gel 0.75% mg for 5 days or ovules 500 mg for 7 days). The recurrence was defined by at least 2 episodes in the previous 12 months. Polybactum® vaginal ovules, day 1-4-7, were started within the 12th and the 24th hr after the end of metronidazole therapy and repeated monthly for 3 cycles.

The first 41 patients enrolled were evaluated for an interim analysis 6 months after the study started; 2 patients interrupted the trial, leaving 39 evaluable subjects. The recurrence rate was significantly reduced compared to previous published data (10.26% vs 40% $p < 0.001$). In 35 patients without recurrence, the assessment of *Lactobacillus* vaginal flora performed by phase contrast microscopy evidenced a significant improvement from baseline ($p = 0.022$). The Investigator global assessment of tolerability was excellent in 38 out of 39 cases.

IMPORTANCE

Bacterial vaginosis (BV) is the most common vaginal disorder in women of childbearing age. In BV, *Lactobacillus* species, which are predominant in a healthy vaginal flora, are replaced by anaerobes, mainly *Gardnerella vaginalis*. BV is responsible for more than 60% of vulvovaginal infections and has been linked to serious, potentially life-threatening

conditions, including: pelvic inflammatory disease, postoperative infections, acquisition and transmission of the human immunodeficiency virus, preterm birth, and several adverse pregnancy outcomes. Our research showed that 3 monthly cycles of Polybactum® ovules administered after one course of metronidazole vaginal therapy can reduce the rate of Bacterial vaginosis recurrence and improve the vaginal milieu, favouring the growth of vaginal lactobacillus species. Taken together our results confirm that Polibactum® is a safe and effective treatment to reduce BV recurrence rate after a first line therapy with metronidazole.

Key words: Bacterial vaginosis, recurrent vaginitis, biofilm, polycarbophil.

INTRODUCTION

Bacterial vaginosis (BV) is the most common vaginal disorder in women of childbearing age (1). In BV, Lactobacillus species, which are predominant in a healthy vaginal flora, are replaced by anaerobes, mainly *Gardnerella vaginalis*, but also *Atopobium vaginae*, *Mobiluncus mulieris*, *Prevotella bivia*, and *Fusobacterium nucleatum*.

BV is responsible for more than 60% of vulvovaginal infections and has been linked to serious, potentially life-threatening conditions, including: pelvic inflammatory disease, postoperative infections, acquisition and transmission of the human immunodeficiency virus, preterm birth, and several adverse pregnancy outcomes (2, 3, 4). Hydrogen peroxide and lactic acid-producing lactobacilli generally dominate the healthy vaginal epithelium, acting as a protective surfactant layer. This leads to an acidic pH that inhibits the adhesion and the growth of other bacteria, including opportunistic pathogens on the vaginal epithelium (5). During the development of BV, the normal vaginal microbiota composition changes, characterized by a decrease in the number of such lactobacilli species and an increase in the number of several pathogenic bacteria, mainly anaerobes (6). Although at least 50% of the infected women have no symptoms, the most common complaints are of abnormal vaginal discharge and fishy odor. Usually, the vulvovaginal

examination normal, apart from a discharge described as watery and gray. A correct diagnosis relies on finding three out of four Amsel criteria (abnormal gray discharge, high vaginal pH, positive amine test, and greater than 20% clue cells on saline microscopy), with a sensitivity of 92%(7). Metronidazole (oral or topical), tinidazole (oral), and clindamycin (oral or topical) are all recommended as initial treatments (8). The etiology and pathogenesis of this disease are not completely understood, because of the various BV-determining risk factors, , and the treatment is not always effective, resulting in high recurrence rates. After treatment, up to 58% of women might have a single recurrence or more within 12 months. Limited data is available regarding optimal management strategies for women with persistent or recurrent BV (8).

Recurrence are relates to the inability to offer a long-term defensive barrier, thus facilitating relapses. Furthermore, the resistance of pathogens to multiple drugs is a (relatively new) health problem that needs alternative treatments to be developed.

Recent studies have found that 90% of women with and 10% without BV have a complex polymicrobial biofilm, which can be demonstrated by electron microscopy of vaginal biopsies. On women with this disease, the biofilm consists primarily of *Gardnerella vaginalis*, sometimes including *Atopobium vaginae* (9). With standard antibiotic regimens, the bacterial load may decrease, but the biofilm may not be eliminated, thus setting the stage for recurrence after treatment. Slime produced by bacteria is a mechanism of forming biofilm that shields and protects microbes against the effects of antibiotics.

The objective of this study was to assess the effectiveness and safety of a new vaginal product that contains polycarbophil, 0.04 % lauryl glucoside, and glycerides (Polybactum®- Effik Italia) in reducing the rate of BV recurrence.

The rationale relates to the specific bacteriostatic action of Polybactum®, which inhibits bacterial growth, and its mucoadhesive property impairing the formation of biofilm produced by *Gardnerella vaginalis* and other bacteria. Furthermore, the product ensures

an acidifying effect on the vaginal pH which favors the growth of lactobacillus microbiota and at the same time maintains a hostile environment for the recolonization of the vagina by the polymicrobial flora involved in BV.

MATERIALS AND METHODS

Trial design. This was a multicenter, open label, not comparative study performed in Italy and Romania. The study protocol was identified with the acronym POLARIS (Polybactum® to assess Recurrent Bacterial Vaginosis) and was approved by the National Agency for Medicines and Medical Devices in Romania (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale), notified to the Italian Ministry of Health and approved by the local Independent Ethics Committees pertaining to the investigational sites. The study was registered in clinicaltrials.gov as NCT02863536 (with attached full protocol).

During the trial, the protocol was amended to allow an interim analysis of 6 months after the start of patient enrolment.

Participants. Female subjects over 18-years-old affected by recurrent BV were included. They were diagnosed based on the Amsel criteria (10) in the 6-9 days before baseline and treated-with metronidazole vaginal formulations (gel for 5 days or ovules for 7 days). The recurrence was defined by at least 2 episodes of (BV) in the last 12 months, including the BV episode treated before baseline. Additional inclusion criteria: informed consent form (ICF) signed before starting the trial and the status of non-lactating women or lactating, but not amenorrhoeic women.

The exclusion criteria: pregnancy; candidiasis or mixed vaginitis; HIV or another immunodeficiency; known allergy to metronidazole or to Polybactum® ingredients; prostitution; ongoing menstruation or pre-menopause/menopause; patients concomitantly included in different interventional clinical trials; unwillingness to provide the informed consent to the trial; time between the last day of last menses and baseline visit >16 days

or ≤ 5 days (to avoid bias in case of a menstrual bleeding occurring during the first cycle with the tested medical device and the consequent need to interrupt its administration); participation in another clinical trial during the last month.

The sites were: Vittore Buzzi Hospital (Milan, coordinator site), AIED Center in Rome (Italy) and 3 private clinics specialized in gynaecology located in Timisoara (Romania). In each center, a lead Investigator was appointed to be responsible for the identification, recruitment, data collection, and completion of Case Report Forms, (CRFs) for patient adherence to protocol and for the sample collections to be transported to the local laboratory. The Investigators were specialists in gynaecology and trained in Good Clinical Practice (GCP). During the study, all the patients presented spontaneously at the Investigator's visit. No advertising was used to increase the enrolment rate.

Interventions. Prior to any study procedure, each patient was informed about the nature and purpose of the trial, the benefits and the risks, and was asked to sign an ICF.

The tested medical device administration (Polybactum[®] vaginal ovule) started within the 12th and the 24th hr after the end of metronidazole vaginal treatment (5 g of 0.75% gel once daily for 5 days or 500 mg ovules once daily for 7 days) and continued for 3 cycles of treatment (minimum 72 and maximum 84 days); the duration of each cycle was one week, with the tested medical device administered as follows: one ovule inserted in the vagina on day 1, one ovule on day 4 and the last ovule on day 7. On the baseline visit, each patient received a total number of 9 ovules for the whole study duration (3 ovules for 3 cycles). The Investigator advised the patient to lay in a supine position for a couple minutes after the ovule had been inserted.

The baseline visit and the first cycle of Polybactum[®] fell within the 6th and the 16th day after the menstrual bleeding and after the end of metronidazole treatment. In the second and the third cycle, Polybactum[®] was administered immediately after the end of the previous menstrual bleeding.

144 In any case, the Investigator could always decide to stop administering the medical device
145 for safety purposes or to prescribe other therapies if considered necessary for the patient's
146 health.

147 The Sponsor, Effik Italia, supplied the investigational product. Patients were reminded to
148 return all investigational product packages to the Investigator. At the end of the study, the
149 Contract Research Organization (CRO) personnel involved in the trial performed the
150 accountability of the tested medical device.

151 During the trial, there were disallowed: vaginal tampons; use of an etonogestrel/ethinyl
152 estradiol vaginal ring (Nuvaring®) or an intrauterine device; oral or vaginal antibiotic
153 therapy or other vaginal therapies (like douching, spermicide); oral or vaginal probiotics
154 (e.g. vaginal lactobacilli); other products or medication to treat BV.

155 **Primary and secondary outcomes.** The primary outcome was the recurrence of BV
156 identified by Amsel criteria (10), determined—at baseline and at final visit; a positive
157 diagnosis of BV required meeting three of the following four criteria:

- 158 • vaginal pH greater than pH 4.5;
- 159 • proportion of clue cells $\geq 20\%$ of total epithelial cells in the vaginal fluid;
- 160 • presence of white and thin vaginal discharge;
- 161 • fishy smell at whiff test.

162 BV was excluded if only two or less criteria were found at baseline. On the other hand, the
163 patient was evaluated as a treatment failure when at least two criteria were met at the final
164 visit. The primary outcome was measured at baseline and the final visit for all patients.

165 The secondary outcomes were the following: vaginal Lactobacillus microbiota assessed by
166 an optical microscopy at baseline and at the final visit to evaluate the vaginal microflora
167 return rate to normality (11) after Polybactum® treatment; signs and symptoms of BV
168 (vaginal discharge, burning, erythema, dyspareunia). Vaginal discharge over the last 24
169 hrs was evaluated using this analogic 3-point scale: 0= not present or physiological in

quantity, colour, and type; 1 = mild abnormal (abnormal quantity with normal colour and type); 2 = abnormal quantity, colour and type.

Burning intensity over the last 24 hrs was evaluated using an analogic 5-point scale: 0 = not present; 1 = mild; 2 = moderate; 3 = severe; 4 = unbearable. Grade of erythema was evaluated using the analogic 5-point scale: 0 = no symptoms; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Dyspareunia was evaluated by a dichotomic scale: 0 = absent; 1 = present. All secondary outcomes were measured at baseline and the final visit considering value change from baseline. Secondary outcome also included the patient assessing the efficacy at the last visit using the 4-point scale: 1 = very good improvement; 2 = good improvement; 3 = moderate improvement and 4 = negligible improvement. Safety was evaluated collecting and analysing the adverse events during the study period and by a global assessment of safety performed by any Investigator using an analogic 4-point scale: 1 = excellent, 2 = good, 3 = fair and 4 = poor.

The study schedule included a visit at baseline (day 0), and a final visit (day 72 to day 84). In addition, the Investigators planned to have 3 phone contacts with the patient: the first at day 28±1 after the last day of last menses, and the following two after 28±1 day apart. On any phone contact the Investigator checked if the patient had any of the BV symptoms and, in this case, performed an unscheduled visit to verify the BV recurrence based on Amsel criteria.

Sample size determination and statistical methods. According to published data, the mean recurrence rate of BV after a first episode is from 30 to 50% within 3 months after a first efficacious medical therapy (12); in the present study patients were not allowed oral or vaginal antibiotic therapy after metronidazole treatment for the 3 month study duration; therefore it should be realistic to have a 40% as mean recurrence rates in this study as well. In addition, in the recently collected data on recurrence rates post-treatment with Polybactum® (Effik Italia SpA, unpublished data), the correlation between paired

observation was 2% and after applying continuity correction, the study would require a sample size of 44 pairs to achieve a power of 80% and a one-sided significance of 5% for detecting a difference of 0.25 between marginal proportions. Considering the drop-out rate, 55 were enrolled (one group chi square test than a proportion equals user specified value non-inferiority). The level of significance of <0.5 was considered statistically significant at 95% confidence interval. If a subject was missing information for one or more variables, the missing data were not replaced. If a subject were involved in violation of inclusion/exclusion criteria, the respective data were excluded from the analysis. Safety was evaluated in terms of adverse event findings. All subjects receiving at least one dose of treatment were included in the safety analysis. Analysis comparing the values between visits was done using t-test or chi squared test for quantitative variables, McNemar test for binary variables and symmetry test for qualitative variables. Kaplan Meier curves were used to analyse the time-to-event regarding BV recurrences. Statistical analysis was performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

Guidelines and legislation. The trial was performed in accordance with UNI EN ISO 14155:2012, the ethical principles of the current version of the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) and the Directive 91/507/EEC, Guidelines for GCP. The privacy of patient data was protected following the current policy in Italy and in Romania.

RESULTS

The data presented are an interim analysis performed 6 months after the first patient enrolled. Participants were recruited in 3 Romanian sites from September 8th, 2016 until December 13th, 2016. As shown in the flow diagram in Figure 1, out of 41 enrolled patients, 2 were excluded from PP analysis because they interrupted the trial for personal reasons not related to safety and 39 subjects were considered evaluable. One patient of these 39 did not complete the study period for intercurrent recurrence.

Age group distribution is summarized in Table 1. Treatment compliance rate (the total number of administered ovules from the total number of given ovules) was 97.01% for all the patients enrolled, and 100% considering only the patients who completed the trial. No relevant findings were evidenced in the medical history and during the physical examination. All the patients completed an antibiotic treatment with metronidazole vaginal formulation (ovules for 7 days) and no concomitant medication was recorded during the screening evaluation.

One of the inclusion criteria stated that only subjects with two or more episodes of BV in the last 12 months should enter the clinical trial. As observed in Table 2, 26 subjects (63.41%) had 2 episodes of BV in the last 12 months, with 12 subjects (29.27%) having 3 episodes of BV, and 3 subjects (7.32%) with 4 episodes of BV.

In the analysis of the primary objective of the study, at the final visit (day 72 to day 84 from baseline), 4 recurrences were identified. Therefore, the recurrence rate of BV after 3 months of treatment with Polybactum® was 10.26% (4 cases in 39). A statistically significant difference ($p < 0.001$) was evidenced comparing this value with recurrence rate data (40%) published in the medical literature (12). To compare the actual recurrences belonging to our data with those from medical literature, we carried out a time-to-event analysis, also called Kaplan-Meier survival curves. Data are censored (the event did not occur during clinical trial period or subject's drop-out) or uncensored (the event occurred during the clinical trial). As observed from Figure 2, after 1 month of treatment, the probability of not having a BV recurrence is 97.6%; the same probability, at the final visit (after 3 months of treatment with Polybactum®) is 89.7%. Therefore, we can conclude that the true recurrence rate of BV after 3 months of treatment with Polybactum® is significantly smaller than the 40% reported by medical literature.

The evaluation of Vaginal Lactobacillus microbiota by microscopy using phase contrast of vaginal secretions was measured from lowest to highest concentration by the following 5-

point scale: absent, 1+, 2+, 3+, 4+ (13) at the baseline visit, and at the final visit (after 3 months of Polybactum® treatment). For 26 out of 39 patients (66.67%) the treatment had a beneficial or neutral effect on the Lactobacillus concentration levels and only in 13 patients (33.33%) the concentration levels worsened (Figure 3). Chi-squared test evidenced that the differences between these values were at the limit of statistical significance (p-value = 0.054). However, analysing the 35 patients without recurrences only, a statistically significant difference (Maxwell-Stuart asymptotic homogeneity test, p-value = 0.022) was evidenced in Lactobacillus concentration levels between baseline and final visit. (Figure 4) Throughout the study period, symptoms associated with BV (vaginal discharge, burning, erythema and dyspareunia) were monitored and recorded by the Principal Investigators in the CRFs and by subjects themselves in the Patient's Diary. The baseline and final data are reported in Table 3. It could be emphasized that the patients with abnormal symptoms at final visit are the four patients with recurrences and 1 additional patient with isolated mild vaginal discharge. These extremely positive results were confirmed by the global assessments of efficacy performed at the end of the study by patients. In fact, it was rated as very good per patient's assessments for 87.18% of them, good for 5.13%, moderate for 2.56%, and negligible for 5.13% of the patients.

During the study, two adverse events have been reported. The cases (mild local itching and mild viral respiratory infection) were evaluated as not related to the tested medical device, recovered after a few days and in both cases the Investigator ruled out the suspicion of BV Recurrence. After the symptoms, the patient who experienced itching dropped out from the study for personal reasons, having completed only 1 cycle of treatment.

The Investigator's global assessment of tolerability was excellent (38 out of 39 cases) for 97.43% and good for 2.57% (1 out of 39) of the patients.

DISCUSSION

274 According to literature data, given the high prevalence of BV, there is an urgent need to
 275 develop products that effectively treat the condition and prevent its recurrence. In our
 276 study, the recurrence rate of BV after 3 months of treatment with Polybactum® was
 277 10.26%, significantly lower than the 40% presented in the medical literature. It is
 278 consented that BV involves the presence of a dense, structured and polymicrobial biofilm,
 279 primarily constituted by *Gardnerella vaginalis* clusters, strongly adhered to the vaginal
 280 epithelium.

281 Since the bacteria within biofilms are not effectively eliminated by the immune system or
 282 fully destroyed by antibiotics, biofilm-related infections tend to persist and thus,
 283 unsurprisingly, BV tends to have a high rate of relapse and recurrence (5).

284 Although the biofilm was shown to contain high concentrations of a variety of bacterial
 285 groups, *Gardnerella vaginalis* was the predominant constituent and it is now accepted that
 286 biofilms in BV are strongly associated with *Gardnerella vaginalis* (14). It was shown that
 287 *Gardnerella vaginalis* was able to adhere to and displace precoated protective lactobacilli
 288 from the vaginal epithelial cells, while other BV-associated anaerobes, such as *Atopobium*
 289 *vaginae* and *Prevotella*, were less virulent (15). Consequently, the current paradigm is that
 290 the establishment of a *Gardnerella vaginalis* biofilm is a required event for initiation and
 291 progression of BV (16).

292 The new product tested in our study contains polycarbophil, 0.04% lauryl glucoside,
 293 glycerides; all constituents that have important effects on the main mechanism involved in
 294 the pathogenesis of BV. In fact, lauryl glucoside has a specific bacteriostatic action which
 295 inhibits *Gardnerella vaginalis* growth. It was proven that *Gardnerella vaginalis* growth is
 296 reduced for 48 hrs by the contact with Polybactum® (already at 24 hrs) (17). The growth of
 297 inhibitory activity of the new vaginal product was also demonstrated against *Streptococcus*
 298 *agalactiae* and *Neisseria gonorrhoeae*. Polybactum® main components are polycarbophil
 299 (a safe film forming agent well known for its lack of toxicity) and lauryl glucoside, a non-

300 ionic surfactant reinforcing the film-forming effect by reducing surface tension. The
 301 combination of these factors gives the product the unique characteristics of a
 302 mucoadhesive property impairing the formation of the biofilm produced by *Gardnerella*
 303 *vaginalis*. Finally, an acidifying effect was observed on the vaginal pH which favors the
 304 growth of lactobacillus microbiota maintaining a hostile environment for the polymicrobial
 305 flora involved in BV to recolonize the vagina. Therefore, vaginal biofilms play a key role not
 306 only in BV pathogenesis, but also in its treatment failure and recurrence. Most proposed
 307 non-antibiotic therapies for BV are vaginal or oral probiotics, with the aim to restore the
 308 normal vaginal microbiota. Several trials evaluated the use of combined metronidazole
 309 and/or clindamycin therapy and vaginal probiotics to prevent BV recurrence, but large,
 310 randomized, placebo-controlled trials with standardized outcomes are needed to confirm
 311 the efficacy of this therapeutic approach for BV (18).

312 Our study focused on demonstrating that the use of Polybactum® in the treatment of BV
 313 not only reduces the rate of relapses, but it also improves the microbiological parameters.
 314 In fact, for 26 out of 35 patients without recurrences (74.28%), the clinical trial had a
 315 beneficial or neutral effect on the Lactobacillus concentration levels. From a clinical point
 316 of view, since metronidazole (the most commonly prescribed antibiotic to treat BV) causes
 317 only transient suppression of the *Gardnerella vaginalis* populations in the vagina (19), the
 318 combined therapy with this antibiotic plus Polybactum® can successfully reduce the
 319 anaerobic bacterial pathogens responsible for BV, delaying or preventing the relapse of
 320 vaginal infection, thus preventing the administration of antibiotics in repetitive courses.

321 Our study has certain limitations, such as the lack of a placebo treatment arm and only a
 322 3-month follow-up after the end of metronidazole treatment. This last problem will be
 323 corrected by the amendment already submitted to the EC to allow a follow up period of 12
 324 months after the end of the antibiotic therapy.

In any case, this study strengthens the evidence supporting the use of specific new vaginal products with well demonstrated activity associated with the creation and maintenance of a vaginal biofilm that hinders the persistence of an infection caused by BV.

ACKNOWLEDGEMENTS

Effik Italia (<http://www.effikitalia.it/>), the study Sponsor, offered a grant support. Effik Italia had no role in the study design, data collection and interpretation, or on the decision to submit the work for publication.

Warm thanks to Ramona Petrita and Andreea-Denisa Toma for support in data management and to Marius Ardelean for statistical analysis.

FM, CC, MB, and DS declare no conflict of interest. DFB is employed at Opera CRO, the Contract Research Organization that managed the study, EC is a medical consultant for Effik Italia, LIA is employed at Effik Italia.

Authors' contribution: FM originally conceived the project; FM and DFB draw up the study design and protocol. The final manuscript was written and approved by all authors.

REFERENCES

1. Schwebke JR, Muzny CA, Josey WE. Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model. J Infect Dis. 2014 Aug 1;210(3):338-43. Available at: <https://doi.org/10.1093/infdis/jiu089>
2. Masson L, Mlisana K, Little F, Werner L, Mkhize NN, Ronacher K, Gamiieldien H, Williamson C, Mckinnon LR, Walzl G, Abdool Karim Q, Abdool Karim SS, Passmore JA. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sex Transm Infect. 2014 Dec;90(8):580-7. Available at: <https://doi.org/10.1136/sextrans-2014-051601>

3. Bretelle F, Rozenberg P, Pascal A, Favre R, Bohec C, Loundou A, Senat MV, Aissi G, Lesavre N, Brunet J, Heckenroth H, Luton D, Raoult D, Fenollar F; Groupe de Recherche en Obstetrique Gynecologie. High Atopobium vaginae and Gardnerella vaginalis vaginal loads are associated with preterm birth. Clin Infect Dis. 2015 Mar 15;60(6):860-7. Available at: <https://doi.org/10.1093/cid/ciu966>
4. Petricevic L, Domig KJ, Nierscher FJ, Sandhofer MJ, Fidesser M, Krondorfer I, Husslein P, Kneifel W, Kiss H. Characterisation of the vaginal Lactobacillus microbiota associated with preterm delivery. Sci Rep. 2014 May 30;4:5136. Available at: <https://doi.org/10.1038/srep05136>
5. Terraf MC, Juárez Tomás MS, Nader-Macías ME, Silva C. Screening of biofilm formation by beneficial vaginal lactobacilli and influence of culture media components. J Appl Microbiol. 2012 Dec;113(6):1517-29. Available at: <https://doi.org/10.1111/j.1365-2672.2012.05429.x>
6. Swidsinski A, Mendling W, Loening-Baucke V, Ladhoff A, Swidsinski S, Hale LP, Lochs H. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005 Nov;106(5 Pt 1):1013-23. <https://doi.org/10.1097/01.aog.0000183594.45524.d2>
7. Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol. 2004 Apr;190(4):1004-10. Available at: <https://doi.org/10.1016/j.ajog.2004.02.015>
8. Sexually Transmitted Diseases: Summary of 2015 CDC Treatment Guidelines. J Miss State Med Assoc. 2015 Dec;56(12):372-5. Available at: <https://doi.org/10.1097/00007435-200306000-00013>
9. Verstraelen H, Swidsinski A. The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr Opin Infect Dis. 2013 Feb;26(1):86-9. Available at: <https://doi.org/10.1097/qco.0b013e32835c20cd>

10. Sha BE, Gawel SH, Hershow RC, Passaro D, Augenbraun M, Darragh TM, Stek A, Golub ET, Mph LC, Moxley MD, Weber KM, Watts DH. Analysis of standard methods for diagnosing vaginitis: HIV infection does not complicate the diagnosis of vaginitis. *J Low Genit Tract Dis.* 2007 Oct;11(4):240-50. Available at: <https://doi.org/10.1097/lgt.0b013e318033dfed>
11. Donders GG. Treatment of sexually transmitted bacterial diseases in pregnant women. *Drugs.* 2000 Mar;59(3):477-85. Available at: <https://doi.org/10.2165/00003495-200059030-00005>
12. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. *J Infect Dis.* 2006 Jun 1;193(11):1478-86. Available at: <https://doi.org/10.1086/503780>
13. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. *J Clin Microbiol.* 1991 Feb;29(2):297-301. Available at: <https://jcm.asm.org/content/29/2/297.short>
14. Swidsinski A, Verstraelen H, Loening-Baucke V, Swidsinski S, Mendling W, Halwani Z. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. *PLoS One.* 2013;8(1):e53997. Available at: <https://doi.org/10.1371/journal.pone.0053997>
15. Machado A, Salgueiro D, Harwich M, Jefferson KK, Cerca N. Quantitative analysis of initial adhesion of bacterial vaginosis-associated anaerobes to ME-180 cells. *Anaerobe.* 2013 Oct;23:1-4. Available at: <https://doi.org/10.1016/j.anaerobe.2013.07.007>
16. Machado A, Cerca N. Influence of Biofilm Formation by *Gardnerella vaginalis* and Other Anaerobes on Bacterial Vaginosis. *J Infect Dis.* 2015 Dec 15;212(12):1856-

61. Available at: <https://doi.org/10.1093/infdis/jiv338>
17. Ardolino LI, Meloni M, Brugali G, Corsini E, Galli CL. Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation. *Curr Ther Res Clin Exp.* 2016 Jul 25;83:13-21. Available at: <https://doi.org/10.1016/j.curtheres.2016.07.002>
18. Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. *Cochrane Database Syst Rev.* 2009 Oct 7;(4):CD006289. Available at: <https://doi.org/10.1002/14651858.cd006289.pub2>
19. Mayer BT, Srinivasan S, Fiedler TL, Marrazzo JM, Fredricks DN, Schiffer JT. Rapid and Profound Shifts in the Vaginal Microbiota Following Antibiotic Treatment for Bacterial Vaginosis. *J Infect Dis.* 2015 Sep 1;212(5):793-802. Available at: <https://doi.org/10.1093/infdis/jiv079>





FIG.1: Flow diagram of the study



Visit	At risk	Failed	Censored	Prop. failed	Survival rate	Survival distribution function	Standard error	Lower bound (95%)	Upper bound (95%)
1	41	1	2	0.024	0.976	0.976	0.024	0.846	0.996
3	38	0	1						
4	37	3	34	0.081	0.919	0.897	0.049	0.768	0.956

FIG 2: Kaplan-Meier survival curve for Bacterial Vaginosis recurrence event




FIG 3: The effect on Lactobacillus concentration level change between baseline and final visit




FIG 4: Lactobacillus concentration values between baseline and final visit on the 35 patients without recurrences (Maxwell-Stuart asymptotic marginal homogeneity test, p-value = 0.022)

483 **TABLE 1** Subjects group distribution by age

<i>Age groups</i>	<i>N</i>	<i>%</i>
18-24 years	12	29.27
25-29 years	10	24.39
30-34 years	10	24.39
35-39 years	5	12.20
> 40 years	4	9.76
TOTAL	41	100.00

484

485 **TABLE 2** Number of patients with multiple BV episodes in the last 12 months by trial site

	Site 4	Site 6	Site 7	TOTAL (%)
2 episodes	0	25	1	26 (63.41)
3 episodes	5	6	1	12 (29.27)
4 episodes	1	2	0	3 (7.32)
TOTAL	6	33	2	41 (100.00)

486

487 **TABLE 3** Number of symptoms and severity at different visits/phone contacts

	<i>Vaginal Discharge</i>	<i>Burning</i>	<i>Erythema</i>	<i>Dyspareunia</i>
<i>Baseline Visit</i>			2 Slight	
<i>1st Phone Contact (1 Month)</i>	4 Mild 1 Abnormal	1 Moderate 1 Unbearable	1 Moderate 1 Marked 1 Very Marked	3 Present
<i>2nd Phone Contact (2 Months)</i>	1 Mild			1 Present
<i>3rd Phone Contact (3 Months)</i>	6 Mild	4 Moderate	4 Moderate	4 Present
<i>Final Visit (3-5 days after last Phone Contact)</i>	4 Mild 1 Abnormal	3 Moderate 1 Severe	1 Slight 2 Moderate 1 Very Marked	4 Present
<i>Number of Symptoms per Visits</i>	17	10	13	12

488 Legend:

489 Vaginal discharge: 0= not present; 1 =mild abnormal; 2= abnormal.

490 Burning: 0 = not present; 1= mild; 2 = moderate; 3 = severe; 4 = unbearable.

491 Erythema: 0 = no symptoms; 1 = slight; 2 = moderate; 3 = marked; 4= very marked.

492 Dyspareunia: 0= absent; 1 = present.